Mobile

Phase II Study of Dasatinib (BMS-354825) for Advanced ‘Triple-negative’ Breast Cancer + Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (version 2.0 dated 16-Aug-06) + Pharmacogenomi...

Mise à jour : Il y a 5 ans
Référence : EUCTR2006-002045-36

Phase II Study of Dasatinib (BMS-354825) for Advanced ‘Triple-negative’ Breast Cancer + Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (version 2.0 dated 16-Aug-06) + Pharmacogenomics Tissue Sample Amendment Number 02 - Site Specific - (version 1.0 dated 16-Aug-06)

Femme Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To estimate objective response rate (ORR) of dasatinib in women with recurrent or progressive locally-advanced or metastatic 'triple-negative' breast cancer.

Critère d'inclusion

  • Recurrent or progressive locally-advanced or metastatic 'triple-negative' breast cancer

Liens